Advertisement
Australia markets close in 4 hours 56 minutes
  • ALL ORDS

    8,034.20
    +31.40 (+0.39%)
     
  • ASX 200

    7,792.50
    +32.90 (+0.42%)
     
  • AUD/USD

    0.6628
    -0.0023 (-0.35%)
     
  • OIL

    82.02
    +0.28 (+0.34%)
     
  • GOLD

    2,331.50
    -5.10 (-0.22%)
     
  • Bitcoin AUD

    92,807.97
    +854.48 (+0.93%)
     
  • CMC Crypto 200

    1,280.98
    +14.83 (+1.17%)
     
  • AUD/EUR

    0.6196
    -0.0010 (-0.16%)
     
  • AUD/NZD

    1.0923
    -0.0004 (-0.03%)
     
  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     
  • NASDAQ

    19,789.03
    +37.98 (+0.19%)
     
  • FTSE

    8,179.68
    -45.65 (-0.55%)
     
  • Dow Jones

    39,164.06
    +36.26 (+0.09%)
     
  • DAX

    18,210.55
    +55.31 (+0.30%)
     
  • Hang Seng

    17,716.47
    0.00 (0.00%)
     
  • NIKKEI 225

    39,715.23
    +373.69 (+0.95%)
     

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

BOSTON, May 30, 2024--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530854297/en/

Contacts

Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com